QTc Bazett-corrected QT interval interpretation on 12-lead ECG
A Bazett-corrected QT interval (QTcB) greater than practical clinical cutoffs is considered prolonged QT and is associated with increased risk of torsades de pointes, especially in the presence of additional risk factors. [1], [2], [3] QTcB categories should be interpreted in the context of heart rate, medication/electrolyte risk, and measurement accuracy. [4], [2]
Practical QTcB cutoffs for labeling QT interval abnormality
The AHA/ACCF/HRS ECG standardization statement defines practical limits for QT interval abnormality as follows. [1]
- QTcB ≥450 ms in men is considered prolonged. [1]
- QTcB ≥460 ms in women is considered prolonged. [1]
-
QTcB ≤390 ms is considered short. [1] The ESC cardio-oncology guideline reports upper 99% limits of normal QTc values in the general population as follows. [2]
-
Upper 99% limit of normal: 450 ms in men. [2]
- Upper 99% limit of normal: 460 ms in women. [2]
Clinical risk thresholds used for torsades de pointes concern
Marked QTc prolongation is generally operationalized using QTc thresholds near or above 500 ms. [3]
- QTc >500 ms is a key high-risk threshold for torsades de pointes in clinical QT safety discussions. [3] The torsades de pointes prevention statement highlights that TdP risk is increased with marked QTc prolongation to >500 ms. [3]
Measurement and correction considerations for QTcB
Bazett’s method overestimates QTc at higher heart rates and underestimates QTc at lower heart rates. [4] Correction method choice should be considered when comparing QT intervals across serial ECGs with changing heart rates. [4] QT measurement requires accurate identification of the end of the T wave, which can be challenging when T waves are notched or when U waves are present. [1]
Monitored comparison across time and the role of ΔQTc
Risk increases with both absolute QTc prolongation and clinically meaningful increases from baseline. [2] The ESC cardio-oncology guideline states that changes in QTc of >60 ms from baseline should not routinely affect treatment decisions when QTc remains <500 ms. [2] The torsades de pointes prevention statement emphasizes that QTc risk is contextual and increases with additional proarrhythmic ECG findings and clinical risk factors. [3]
Risk factor clustering used when interpreting QTcB
Interpretation should incorporate predisposing factors for QT prolongation and torsades de pointes. [2], [3] Common non–dose-independent risk factors include female sex, age >65 years, baseline QTc prolongation, family history of sudden death or congenital long QT syndrome, impaired renal function, and pre-existing cardiovascular disease. [2] Common modifiable contributors include hypokalemia and hypomagnesemia. [2]
Common pitfalls in QTcB interpretation
Bazett correction can misclassify QT prolongation severity when heart rate is not stable across ECGs. [4] Misidentification of the T-wave end can alter QTc calculation, particularly with notched T waves. [1] Overreliance on a single automated QTcB value without clinical context can miss important changes in electrolytes, interacting medications, or other torsades risk markers. [2], [3]
Clinical approach when QTcB is prolonged
If QTcB meets the practical prolonged QT cutoffs, the ECG should be treated as abnormal and prompts reassessment of reversible contributors such as interacting drugs and electrolyte disturbances. [1], [2] Marked QTc prolongation (generally >500 ms) is associated with substantially higher torsades de pointes risk and should trigger urgent risk mitigation and specialty-level evaluation per local protocols. [3] Serial ECG assessment is recommended in contexts where QTc is expected to change due to medication initiation or dose modification, with attention to correction method limitations (Bazett) and heart rate trends. [2], [4]